light-mediated

C-MS023 is a photoactivatable prodrug of MS023, designed to achieve spatiotemporal inhibition of Histone Arginine Asymmetric Dimethylation. It specifically inhibits PRMT6-mediated asymmetric dimethylation of H3 Arginine 2 (H3R2me2a) with an IC50 of approximately 0.2224 μM. The photolysis of C-MS023 can be triggered by exposure to 420 nm visible light, releasing MS023, which effectively downregulates histone arginine asymmetric dimethylation and transcriptional activities related to DNA replication.

IgG has four forms, provides the majority of antibody-based immunity against invading pathogens. The only antibody capable of crossing the placenta to give passive immunity to the fetus. Eliminates pathogens in the early stages of B cell-mediated (humoral

Porfimer sodium is t he sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm w

Optovin is a TRPA1 activator, which is reversibly photoactivated.

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal immunoglobulin G1 (IgG1) antibody specifically targeting the serum amyloid P component (SAP), a protein universally found in all types of amyloid deposits, and it possesses potential anti-amyloid activity by triggering an immunotherapeutic mechanism for the clearance of amyloid fibrils through macrophage-mediated phagocytosis, which can be applied in the research of amyloid light-chain (AL) amyloidosis and other systemic amyloid diseases.

CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) that specifically targets Ca2+ calmodulin-dependent protein kinase II α (CaMKIIα), facilitating its ubiquitination and subsequent proteasome-mediated degradation when exposed to specific light wavelengths. Under illumination, CaMKIIα-PHOTAC diminishes synaptic functions and weakens evoked field excitatory postsynaptic potentials in the mouse hippocampus, impacting physiological responses and sustaining long-term potentiation and memory functions within dendritic domains [1].

Nocarnickelamides B (Compound 2) is a linear peptide and an inhibitor of ROCK1 2. It exhibits dual inhibitory activity against ROCK1 and ROCK2, with IC50 values of 14.9 μM and 21.9 μM, respectively. This compound binds to the ATP binding site and inhibits ROCK-mediated cytoskeletal contraction markers, such as myosin light chain activation. Nocarnickelamides B can be utilized in glaucoma research.